Bristol Myers Squibb Reports Phase 2 Results From Registrational QUINTESSENTIAL Trial Of Arlocabtagene Autoleucel In Quadruple-Class Exposed RRMM Patients; Trial Met Primary Endpoint Of Overall Response Rate And Key Secondary Endpoint Of Complete Response Rate
Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated patient population who have been exposed to a prior BCMA-targeted therapyQUINTESSENTIAL
Bristol Myers Squibb's new cancer medicine worked well in sick patients who had tried many treatments before. When a company's medicine reaches its goals in testing, it's a sign the company's plan is moving forward—something to watch as they work toward approval.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.